FDA approves single-trial pathway for Cambium Bio
Cambium Bio (ASX:CMB) announced that the US Food and Drug Administration confirmed a streamlined approval pathway for its flagship candidate, Elate Ocular.
Cambium Bio (ASX:CMB) announced that the US Food and Drug Administration confirmed a streamlined approval pathway for its flagship candidate, Elate Ocular.
Dicker Data (ASX:DDR) appointed Fiona Brown as Managing Director to drive long-term strategic growth.
MB Gold (ASX:MBG) commenced a major reverse circulation drilling programme at the highly prospective Marble Bar Gold Project.
XRF Scientific (ASX:XRF) announced the acquisition of the combustion gas analysis business from Bruker AXS SE.
West African Resources (ASX:WAF) maintains its 2026 production guidance of 430,000–490,000 oz gold following a robust Q1.
Firebird Metals (ASX:FRB) has been awarded a $2 million grant from the federal government.
Resolution Minerals (ASX:RML) secured $20 million through a successful institutionally-led placement.
The Future Fund has appointed Richard Brandweiner as its new chief investment officer.
Adisyn (ASX:AI1) secured commitments for an $14 million institutional placement.
Resolute Mining (ASX:RSG) has reported a 9.6% decline in quarterly gold production, attributed largely to rising operational headwinds.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy
